Navigation Links
Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
Date:10/19/2007

NATICK, Mass., Oct. 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2007, as well as guidance for net sales and earnings per share (EPS) for the fourth quarter of 2007.

Highlights

- Reported net sales of $2.048 billion, which was at the mid-point of

guidance, and adjusted EPS of $0.20, which exceeded guidance

- Attained number one position in the worldwide drug-eluting stent (DES)

market

- Achieved DES market share leadership in Japan

- Reached 56 percent market share in the U.S. DES market, up from

54 percent last quarter

- Reported year-over-year worldwide cardiac rhythm management (CRM) sales

growth of 16 percent, including implantable cardioverter defibrillator

(ICD) growth of 18 percent

- Announced several new initiatives designed to increase shareholder

value, including the planned sale of business units, and expense and

head count reductions

- Amended the Company's term loan agreement, providing increased

financial flexibility, while prepaying $1 billion of the loan

Net sales for the third quarter of 2007 were $2.048 billion as compared to $2.026 billion for the third quarter of 2006. Worldwide sales of the Company's drug-eluting coronary stent systems for the third quarter of 2007 were $448 million as compared to $572 million for the third quarter of 2006. U.S. sales of drug-eluting coronary stent systems for the third quarter of 2007 were $240 million as compared to $384 million for the third quarter of 2006. International sales of drug-eluting coronary stent systems were $208 milli
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. The birth of biotech: San Francisco, Boston, Geneva or Chicago?
2. Wicab to present BrainPort at Boston conference
3. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
4. Boston entrepreneur to enliven Milwaukee angel group
5. UW-Madisons Beebe wins scientific award
6. Researchers say scientific reporting needs more perspective, less hype
7. Wisconsin stands at the center of scientific efforts to avert flu epidemics
8. Growth prompts new location for scientific instrument manufacturer
9. UW stem cell guru outlines scientific and political future
10. Wisconsin biotech sector featured in scientific magazine
11. Scientific Protein Laboratories Acquired by New York firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... were treated with a statin in the hospital after ... to survive than those who were not, according to ... This study was conducted by the same researchers who ... improve survival in victims of ischemic stroke., Ischemic stroke ... blood vessel that blocks blood from reaching areas of ...
(Date:9/22/2014)... Research and Markets ( ... "Global Biotechnology Reagents Market 2014-2018" report ... Biotechnology reagents are chemical compounds or ... detect and examine another substance to provide a ... to prepare, collect, and examine specimens from the ...
(Date:9/22/2014)... (CTCs) in a mouse model of pancreatic cancer identified ... CTCs, including significant differences from the primary tumor that ... In their study reported in the Sept. 25 issue ... General Hospital (MGH) Cancer Center identified several different classes ... prove to be targets for improved treatment of the ...
(Date:9/22/2014)... Researchers have discovered a way to create a highly ... graphene sheets. The imperfections have unique electronic properties that ... to absorbed gas molecules by 300 times. , The ... Nature Communications . , Amin Salehi- Khojin, asst ... with Mohammad Asadi, graduate student and Bijandra Kumar, post ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Graphene imperfections key to creating hypersensitive 'electronic nose' 2
... of investigational sustained follicle stimulant achieves similar efficacy to ... week period in Phase III Study , , ... SGP ) today announced results from the Phase III ... corifollitropin alfa, first in the class of sustained follicle ...
... a subsidiary of Eisai Corporation of North America, announced ... express and develop therapeutic monoclonal antibodies for the potential ... , , Under the terms of the agreement, ... technology and its expertise to produce and develop a ...
... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that ... device and methods for linking biological agents to labels for ... as In-Line labeling, was developed for the production of radiolabeled ... A study published today in the July 2009 issue ...
Cached Biology Technology:Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 2Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 3Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 4Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 5Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 6Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 7Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 8Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 9Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 2Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 4
(Date:9/22/2014)... the University of Chicago have shown that after a ... a handful of pathogenic microbe species remain behind in ... discovered that some can become deadly when provoked by ... , The findings, published in mBio , the ... may lead to better monitoring and treatment of ICU ...
(Date:9/22/2014)... --- Many native species have vanished from tropical ... Florida scientists have discovered how fossils can be ... key lies in organic materials found in fossil ... functioned, according to a new study available online ... Journal of Herpetology . Pre-human island ecosystems provide ...
(Date:9/22/2014)... of cut grass in recent years has been identified ... research says the aroma also summons beneficial insects to ... the plant signals the environment via the emission of ... queue for parasitic wasps to come to the plant ... pest insect," said Dr. Michael Kolomiets, Texas A&M AgriLife ...
Breaking Biology News(10 mins):Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Answer to restoring lost island biodiversity found in fossils 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3
... at St. Jude Children's Research Hospital have discovered how a ... effects ranging from learning and memory capabilities to glucose production ... called CREB, is a transcription factor—a molecule that binds to ... gene to make the specific protein for which it codes. ...
... provides the most compelling evidence to-date that some dinosaurs ... del Campo track site in Spain's Cameros Basin, contains ... a non-avian therapod dinosaur. , A team led ... La Rioja, Spain, discovered the prints in an area ...
... guys that help bacterial pathogens do their job of infecting ... essence, they knock down the front door of resistance and ... University of California, San Diego (UCSD) School of Medicine have ... YpkA, one of several effectors of the bacteria Yersinia – ...
Cached Biology News:St. Jude study shows genes play an unexpected role in their own activation 2Definitive evidence found of a swimming dinosaur 2How plague-causing bacteria disarm host defense 2
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Biology Products: